This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MOUNTAIN VIEW, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- A new comprehensive treatment algorithm for diabetes from the American Association of Clinical Endocrinologists (AACE) is the first to recommend active obesity management, which includes lifestyle modification and, if appropriate, the use of FDA-approved anti-obesity medications, as first-line therapy in the management of chronic cardiometabolic diseases, including prediabetes, diabetes, dyslipidemia and hypertension.
"As a respected and influential institution in the field of endocrinology, it is encouraging to see the AACE has addressed the critical role of effective medical obesity treatments in the management of chronic cardiometabolic disease," said Peter Tam, president of VIVUS, Inc. (Nasdaq:VVUS) "Endocrinologists are the thought leaders in weight management and metabolic diseases, and we believe that healthcare providers, including primary care physicians, along with payors and public policy makers, will recognize the significance of these new guidelines."
AACE Comprehensive Diabetes Management Algorithm 2013 will be presented and discussed during the AACE 22nd Annual Scientific and Clinical Congress, May 1 – 5, 2013 in Phoenix, AZ. The guidelines are available
online and in the March/April 2013 issue of
Endocrine Practice.About Qsymia
® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m
2 or greater (obese) or 27 kg/m
2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.